【财华社讯】福田股份(08196.HK)今日盘中一度涨逾45%，截至发稿，涨32.1%，报1.07港元。消息面 上，该公司公布，8月5日公司拟配售最多758.748万股配售股份，相当于经配发及发行配售股份而扩大 后的已发行股本约16.67%。每股配售价0.73港元，较于配售协议日期在联交所所报的收市价每股股份 0.81港元折让约9.88%。预期配售事项所得款项净额(经扣除应付配售代理的配售佣金及配售事项产生的 其他开支)将约为546万港元。公司拟将所得款项净额用作集团的一般营运资金。 本文源自财华网 ...

Core Viewpoint - The company, Zhaoke Ophthalmology-B (06622), has seen a significant stock price increase of over 35% this week, with a current price of HKD 3.78 and a trading volume of HKD 22.5882 million, following the announcement of obtaining a medical device registration certificate for TONO-i from the National Medical Products Administration of China [1] Group 1: Product Development - The TONO-i device will be a crucial part of the company's glaucoma medical product portfolio, addressing the demand gap in China for low diagnosis and treatment rates [1] - TONO-i provides ophthalmologists with a tool to easily, accurately, and thoroughly monitor patients' intraocular pressure, which aids in delivering immediate and continuous feedback on treatment efficacy, thereby improving patient compliance with glaucoma medication [1] - The introduction of TONO-i into the company's pipeline signifies its commitment to a dual approach in glaucoma management, focusing on both treatment and diagnosis [1] Group 2: Distribution Agreement - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the field of developing diagnostic, therapeutic, and preventive medical devices for glaucoma [1] - Under the terms of the agreement, the company holds exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, which were later expanded to include Thailand and Malaysia, effective from August 2024 [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant stock price increase, rising over 7% and nearly 35% this week, indicating strong market interest and confidence in the company's future prospects [1] Company Developments - The company has obtained a medical device registration certificate for TONO-i from the National Medical Products Administration, which will be a key part of its glaucoma medical product portfolio [1] - TONO-i is designed to provide ophthalmologists with a tool to easily, accurately, and thoroughly monitor patients' intraocular pressure, thereby improving patient adherence to glaucoma medication treatment [1] - The introduction of TONO-i into the company's pipeline underscores its commitment to dual approaches in glaucoma management, focusing on both treatment and diagnosis [1] Strategic Partnerships - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the field of glaucoma diagnostic, treatment, and prevention medical devices [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, with rights later expanded to include Thailand and Malaysia, effective from August 2024 [1]

Group 1 - The stock of Uni-President China (00220) has dropped over 4%, currently down 4.21% at HKD 9.11, with a trading volume of HKD 44.5484 million [1] - The company will hold a board meeting today to approve the interim results for the six months ending June 30, 2025 [1] - According to a previous report by CICC, the company is expected to see an 8.5% year-on-year increase in revenue for the first half of this year, with net profit projected to rise by 25% to HKD 1.2 billion, aligning with market expectations [1] Group 2 - The beverage business is anticipated to face intensified competition as it enters the peak season in the second quarter, leading to a slowdown in revenue growth [1] - Specifically, the iced tea segment is expected to be under pressure due to competitors entering the similar sugary tea category, increasing competition [1] - In contrast, the company's green tea and milk tea segments are expected to continue their healthy growth trend, with overall beverage revenue projected to achieve mid-to-high single-digit growth year-on-year for the first half [1]

飞机将促进未来增长及逐渐取替公司部分的现有长途宽体飞机机队。该等飞机将主要服务长途航线，同 时亦服务指定区域航点。 【财华社讯】国泰航空(00293.HK)公布，CPAS行使2013年认购协议项下购买权以购买14架波音777-9型 飞机；及获制造商授予购买额外最多7架波音777-9型飞机的权利。 飞机基本价格包括机身价格、附加部件价格及发动机价格。飞机的飞机基本价格约为81亿美元(折合约 为632亿港元)。制造商就飞机给予CPAS大幅价格优惠。该价格优惠乃双方按公平原则磋商后厘定，因 此飞机的实际代价较上述的飞机基本价格为低。交易的全部或部分资金拟通过商业银行贷款、融资租 赁、售后回租安排及/或由公司业务营运产生的现金提供。 购买每架飞机的代价须分五期以现金支付，每架飞机的首四期款额将于该飞机付运前支付，占代价相当 大部分的余款将于该飞机付运时支付。公司预期飞机于2034年或之前付运。 本文源自财华网 ...

预期报告期间录得未经审核公司拥有人应占合并溢利主要由于报告期间完成以作价人民币6.61亿向公司 控股股东一名联系人出售若干发电资产而产生其他收入及偿还银行借款致使利息支出减少。 伟能集团(01608)发布公告，预期截至2025年6月30日止六个月录得未经审核公司拥有人应占合并溢利约 2000万港元，2024年同期录得公司拥有人应占合并亏损约1.39亿港元。 ...

Group 1 - Songjing Technology (1079.HK) resumed trading with a significant increase, soaring by 79.56% at one point, reaching HKD 0.246, with trading volume exceeding HKD 31 million [1] - The company announced that original shareholders Zhang Sanhuo and Yang Taomei transferred 53.83% of the company's equity to an independent third party, Yuwei (the offeror), involving 714 million shares for a total cash consideration of HKD 48.45 million [1] - Following the completion of the transfer, the offeror is required to make a mandatory general offer at a cash price of HKD 0.068 per share, representing a discount of 50.36% compared to the closing price before the suspension [1]

8月6日，三生制药(01530)盘中下跌5.02%，截至13:34，报30.68元/股，成交9.27亿元。 三生制药是中国领先的生物制药企业，专注于创新药物的研发、生产与销售，拥有约30种上市产品和31 个在研产品，核心产品在各自治疗领域市场占有率领先。公司具备覆盖生物药全生命周期的研发及 CDMO能力，在全球设有6大生产基地，2023年CDMO产能达7.6万升，并拥有2600余名医学代表构建广 泛学术推广网络。 截至2024年年报，三生制药营业总收入91.08亿元、净利润20.9亿元。 本文源自：金融界 作者：行情君 ...

Group 1 - The stock of Songjing Technology (01079.HK) resumed trading and surged, with an increase of 73% to HKD 0.235, and a trading volume of HKD 31 million [1] - The offeror, Yu Wei, proposed a full acquisition offer at HKD 0.068 per share, covering 53.83% of the company's equity, with a total consideration of HKD 48.45 million [1] - This offer represents a discount of 50.36% compared to the stock price before the suspension [1] Group 2 - Yu Wei is an executive director and fund manager at Qiyuan Zhide, focusing on the computer components and systems industry [1] - After the completion of the offer, the offeror intends to maintain the company's listing status [1]

消息面上，国泰航空午间发布2025年中期业绩，集团收益543.09亿港元，同比增长9.5%；股东应占溢利 36.51亿港元，同比增长1.1%；中期息每股20港仙。公告指出，其全资拥有的低成本航空公司香港快运 于上半年录得除财务支出净额及税前亏损5.24亿港元，去年上半年除财务支出净额及税前溢利6600万港 元，主要是由于旅客受地震传闻影响而暂时避免前往日本等传统热门目的地，以及新增的航线需时才发 展成熟。 国泰航空(00293)午后跌超9%，截至发稿，跌8.99%，报10.93港元，成交额1.88亿港元。 此外，国泰宣布行使2013年认购协议项下的购买权，购入14架波音777-9型飞机，同时获授额外最多7架 同型号飞机的认购权。14架飞机的基本价格约81亿美元，折合约632亿港元，由于制造商将提供大幅价 格优惠，预期实际代价较上述基本价格为低。 ...